Drug intelligence / Profile preview

EYED-002

Development stage: Phase 2
Lead developer: EyeDura Therapeutics
Administration: Ophthalmic

Overview

EYED-002 is an investigational hormone-based therapy developed for ophthalmic indications, specifically targeting neurotrophic keratitis. The drug is in preclinical development. Detailed mechanistic information such as the molecular target and mechanism of action are not disclosed in publicly available sources.

Brand names: EYED-002EYED002EYED 002
Other names: EYED-002EYED002EYED 002

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on EYED-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EYED-002.

Explore the full profile